CRISPR Therapeutics AG (CRSP) News

StockCharts 3 year history with 20% ZigZag reversals................



CRSP seems to be suffering from lack of 'sponsorship' in that the stock has not shown "accumulation" trend along with the price rally since last year's October Low. There's been volume, but not accumulation bias.

Best wishes,
OAG

Hi MD,
CRSP is now down around 1/3 from its February high. The price is where I usually start to accumulate more shares.

Best wishes,
OAG

CRSP over $30

Upcoming https://uk.finance.yahoo.com/news/crispr-therapeutics-present-american-society-120000624.html

CRSP new 52 week high

Early Barchart 100
https://www.barchart.com/stocks/performance/percent-change/advances?timeFrame=today&viewName=main&screener=overall&orderBy=percentChange&orderDir=desc

CRSP new 52 week high

CRSP new 52 week high

They entered into an investment agreement for the sale of ~$280 million of its shares to a select group of institutional investors in a registered direct offering, at $71.5 apiece. The financing is being led by EcoR1 Capital and SR One with participation from existing investors and a healthcare specialist investor https://finance.yahoo.com/news/crispr-therapeutics-announces-280-million-133000932.html

EU approval https://finance.yahoo.com/news/european-commission-approves-first-crispr-065900771.html

Didn’t tank like BLUE
Recovered


More analysis from Nanolyze

So there has been some discussion since my last post
More in this podcast

Around two months ahead of expectations https://www.globenewswire.com/news-release/2024/01/16/2810298/0/en/CRISPR-Therapeutics-Announces-U-S-Food-and-Drug-Administration-FDA-Approval-of-CASGEVY-exagamglogene-autotemcel-for-the-Treatment-of-Transfusion-Dependent-Beta-Thalassemia.html

Strategic Priorities and 2024 Outlook https://finance.yahoo.com/news/crispr-therapeutics-highlights-strategic-priorities-120000043.html

Webcast link https://jpmorgan.metameetings.net/events/healthcare24/sessions/49607-crispr-therapeutics-inc/webcast/general_signin?gpu_only=true&kiosk=true

Upcoming https://uk.finance.yahoo.com/news/crispr-therapeutics-present-42nd-annual-133000024.html

Good morning OAG,

Surprising and interesting. Share price sudden "jack-rabbit" moves in quick price reversals. The technical picture for today changed from positive breakout yesterday to "High Pole Warning" with sudden drop in price. Apparently the dominating group of participants seem to dictate this pace a bit unusual and different from other stocks. Yet it offers opportunity for profit once one has a good plan and strategy.

Good you have a plan and strategy for your preferred limits and ranges for your trading. Let's see how it goes. Have fun & GLTY

Good morning JJ8,

It needs to crest $85 or better to get me interested in reducing my share inventory. A drop to $57 will trigger an addition of 12% to share count.

I'd like to see it crest $72 and maintain that price right now.

Best wishes,
OAG

CRSP share price Double Top Breakout today on 19-Dec-2023. Happy Holidays & GLTA

Oscar Wilde once observed that a cynic knows the price of everything and the value of nothing

Windbag1014,

Thanks for your views and informative response. GLTY & GLTA

OldAIMGuy,

Thanks for your clear and detailed response.

Your approach and strategy dealing with what Crispr T AG stock price movement over time shows, and the Crispr company activity makes good sense. More power and good luck to you.

John

Hi JJ8, Re: CRSP price action..........................

My guess is it's a "Sell on the News" action. This isn't the first time CRSP has shown high amplitude price change as this histogram shows:
https://schrts.co/NSfSbXYF

I think it will be important to watch the transition of this company from basically a 'research' business to one of product development and distribution. Somewhere along the way they'll have to show a profit to reward those who've invested in them. I'm fond of watching the Accumulation/Distribution activity to see what is happening with strong and weak hands holding the stock. In the mean time I plan on trimming and backfilling my position as the price moves around. I last added 12% to my position at $47.56 in August and had the opportunity to part with 10% of the holding at $69.57 a few weeks ago. The core position remains.



With each cycle of the price the portfolio builds out a bit.

Hope this helps,
OAG

Vertex set the price of Casgevy at $2.2 million compared to $3.1 million for Bluebird’s Lyfgenia. Bluebird’s gene therapy for thalassemia, approved last year, has a list price of $2.8 million.

The therapies are also not easy to receive. Patients must spend weeks, even months, in the hospital before and after the therapy is administered. And some of the preparatory steps can cause serious side effects, including severe infections, nausea, painful mouth sores, and infertility.

https://www.statnews.com/2023/12/08/fda-approves-casgevy-crispr-based-medicine-for-treatment-of-sickle-cell-disease/#:~:text=Vertex%20set%20the%20price%20of%20Casgevy%20at%20%242.2,year%2C%20has%20a%20list%20price%20of%20%242.8%20million.

Prohibitive treatment

Probably just because the share price had run up so much before the approval, so it was kind of baked-in already and some took profits. Also, maybe because of high price tag of the treatment. Still a bright future and should trend upwards.

The dump of Crisp shares last Friday Dec 8th after the "good" news is confusing.

The institutional ownership is 63.48%. Why this response by share owners. I assume it probably was mainly by the institutions. But why at this time? Profit taking? Haven't done a check on insiders transactions yet.

More than 17 million shares traded in one session. The average daily volume of trading happens to be about 2-3 millions of shares daily. Why the exodus a this time of "good" news.

My profits were cut in half in one session. I don't intend to sell at such times.
Actually, I buy usually. That's what I did recently after the sudden drop in Walmart share price.

Any ideas and thoughts? What's going on behind the scene? TIA

GLTA

Emmanuelle Charpentier, age 54, founder of Crispr Therapeutics AG

Casgevy, developed by partners Vertex Pharmaceuticals (VRTX) and CRISPR Therapeutics (CRSP), and bluebird bio's (BLUE.) Lyfgenia were approved for people aged 12 years and older.
https://www.reuters.com/business/healthcare-pharmaceuticals/us-approves-two-gene-therapies-sickle-cell-disease-2023-12-08/

CRSP share price sharp reversal by Double Bottom Breakdown today on 8-Dec-2023. This type of rapid reversals based on company news developments. C'est La Vie in stock trading. GLTA

U.S. approves first gene-editing treatment, Casgevy, for sickle cell disease https://www.cnbc.com/2023/12/08/casgevy-first-crispr-gene-editing-treatment-approved-in-us.html?__source=iosappshare%7Ccom.apple.UIKit.activity.CopyToPasteboard

What are the bleep are you talking about without pasting a chart to back up your assertion

CRSP share price Spread Triple Top Breakout today on 06-Dec-2023. GLTA

Smart move. Don't waste resources, learn from the clinical data and improve the pipeline https://finance.yahoo.com/news/crispr-therapeutics-announces-updates-immuno-211500451.html

Is the 12/8 FDA approval in the price already?

CRSP share price Low Pole Reversal today on 04-Dec-2023. We had 3 sessions of trading in Dailies that was in Downtrend while the Weeklies are in Uptrend. It seems the Weeklies more likely to continue should this week the trend in Dailies continue to keep support of the Weekly Uptrend. We shall see. GLTA

UR welcome
I came across CRSP three years ago and learned about the discoverers of the technology, Jennifer Doudna and Emmanuelle Charpentier who shared the 2020 Nobel for chemistry
I have been following the technology since, including Jennifer Doudna’s Nobel lecture
Clustered
Regularly
Interspersed
Short
Palindromic
Repeats

Interesting and informative analysis. Thanks for posting. GLTY & GLTA

Older YouTube interview with Sam Kulkarni CRSP CEO

Good capsule analysis by a YouTuber
Not all of them are shills

CRSP share price Double Bottom Breakdown today on 30-Nov-2023. The Daily turned Downtrend in this trading session while the Weeklies are still in Uptrend as of this week. We shall see what path it may choose to follow. I am optimistic for the long term at this time.

We should get data from the VCTX210 and VCTX211 trials next year https://news.ubc.ca/2023/11/27/stem-cell-based-treatment-for-type-1-diabetes/

9:10 am ET November 29, 2023 (Benzinga) Print
On CNBC’s "Mad Money Lightning Round," Jim Cramer said he would not buy CRISPR Therapeutics AG (NASDAQ: CRSP) stock "all the way up here. I think it’s got to come down a little because the stock is losing a lot of money."

Ok so maybe the FDA approval on Dec. 8th is already built into the price of CRSP during it's recent surge? That is kind of what I am thinking that if they do get the approval, that maybe it doesn't go up much more if any at all? But VRTX going down on the UK day of approval seems to me a puzzle?

The Wall Street Journal: https://apis.mail.aol.com/ws/v3/mailboxes/@.id==VjN-hiBNZAcI-lM8ByCu6y6Fx8t6dU8_Ph3pmNGylKIWMjCXfC_x8h62mmwyIcmu_FBw/messages/@.id==AKCdX-kLfEQZZWTGCgS3CFXbnrk/content/parts/@.id==2/thumbnail?appid=AolMailNorrin&downloadWhenThumbnailFails=true&pid=2

Yes, it has a bright future, and it will help so many patients along the way!

Wall Street Analysts Believe CRISPR Therapeutics AG (CRSP) Could Rally 33.75%: Here's is How to Trade
9:55 am ET November 20, 2023 (Zacks) Print
CRISPR Therapeutics AG (CRSP) closed the last trading session at $67.89, gaining 75.8% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $90.80 indicates a 33.8% upside potential.

The mean estimate comprises 20 short-term price targets with a standard deviation of $46.01. While the lowest estimate of $42 indicates a 38.1% decline from the current price level, the most optimistic analyst expects the stock to surge 224.1% to reach $220. It's very important to note the standard deviation here, as it helps understand the variability of the estimates. The smaller the standard deviation, the greater the agreement among analysts.

While the consensus price target is a much-coveted metric for investors, solely banking on this metric to make an investment decision may not be wise at all. That's because the ability and unbiasedness of analysts in setting price targets have long been questionable.

But, for CRSP, an impressive average price target is not the only indicator of a potential upside. Strong agreement among analysts about the company's ability to report better earnings than they predicted earlier strengthens this view. While a positive trend in earnings estimate revisions doesn't gauge how much a stock could gain, it has proven to be powerful in predicting an upside.

Here's What You Should Know About Analysts' Price Targets

According to researchers at several universities across the globe, a price target is one of many pieces of information about a stock that misleads investors far more often than it guides. In fact, empirical research shows that price targets set by several analysts, irrespective of the extent of agreement, rarely indicate where the price of a stock could actually be heading.

While Wall Street analysts have deep knowledge of a company's fundamentals and the sensitivity of its business to economic and industry issues, many of them tend to set overly optimistic price targets. Are you wondering why?

They usually do that to drum up interest in shares of companies that their firms either have existing business relationships with or are looking to be associated with. In other words, business incentives of firms covering a stock often result in inflated price targets set by analysts.

However, a tight clustering of price targets, which is represented by a low standard deviation, indicates that analysts have a high degree of agreement about the direction and magnitude of a stock's price movement. While that doesn't necessarily mean the stock will hit the average price target, it could be a good starting point for further research aimed at identifying the potential fundamental driving forces.

That said, while investors should not entirely ignore price targets, making an investment decision solely based on them could lead to disappointing ROI. So, price targets should always be treated with a high degree of skepticism.

Here's Why There Could be Plenty of Upside Left in CRSP

Analysts' growing optimism over the company's earnings prospects, as indicated by strong agreement among them in revising EPS estimates higher, could be a legitimate reason to expect an upside in the stock. That's because empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.

For the current year, 11 estimates have moved higher over the last 30 days while one has gone lower. As a result, the Zacks Consensus Estimate has increased 26.2%.

Moreover, CRSP currently has a Zacks Rank #2 (Buy), which means it is in the top 20% of more than the 4,000 stocks that we rank based on four factors related to earnings estimates. Given an impressive externally-audited track record, this is a more conclusive indication of the stock's potential upside in the near term. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>

Therefore, while the consensus price target may not be a reliable indicator of how much CRSP could gain, the direction of price movement it implies does appear to be a good guide.

https://www.fool.com/investing/2023/11/14/2-stocks-to-buy-hand-over-fist-as-market-rallies/?source=eptyholnk0000202&utm_source=yahoo-host&utm_medium=feed&utm_campaign=article&yptr=yahoo

Yes, exciting times!

Yes that would be huge.

Nice, Dad! Yeah, December 8th is when we expect FDA approval...

-Exa-cel PDUFA target action date is December 8, 2023 for severe sickle cell disease (SCD)-

ZUG, Switzerland and BOSTON, Oct. 31, 2023 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP) today announced the completion of the U.S. Food and Drug Administration’s (FDA) Cellular, Tissue, and Gene Therapies Advisory Committee meeting for exagamglogene autotemcel (exa-cel) for the treatment of SCD in people ages 12 and older with recurrent vaso-occlusive crises (VOCs). Exa-cel is the first potential therapy to emerge from a strategic partnership between CRISPR Therapeutics and Vertex Pharmaceuticals.

If approved, exa-cel could be the first genetic therapy available to approximately twenty thousand people with severe SCD in the U.S. The FDA granted priority review for exa-cel in the treatment of people with SCD and assigned a Prescription Drug User Fee Act (PDUFA) action date of December 8, 2023. Exa-cel’s Biologics License Application (BLA) for transfusion-dependent beta-thalassemia (TDT) was assigned a PDUFA date of March 30, 2024.